Skip to main content
. Author manuscript; available in PMC: 2016 Dec 15.
Published in final edited form as: Clin Cancer Res. 2015 Jul 17;21(24):5543–5551. doi: 10.1158/1078-0432.CCR-14-2009

Figure 3. Therapeutic activity of oncolytic vaccinia in combination with anti-CTLA4 antibody is viral strain dependent.

Figure 3

2×108 pfu of oncolytic Vaccinia Virus (B18R- or vvDD) were administrated intravenously to Balb/c mice bearing subcutaneous Renca tumors. At days 4, 7 and 10 after virus injection, a dose of 100 μg of anti-CTLA4 antibody was injected intraperitoneally. B18R- displayed greater inhibition of tumor growth relative to vvDD. Relative tumor volume after virus administration is plotted (n=12–15 mice/group +SE). (* P<0.05 compared with PBS group; φ P<0.05 compared with vvDD+anti-CTLA4 day 4 group).